探索淋巴瘤与骨髓纤维化之间的分子机制。
Exploring the molecular mechanisms between lymphoma and myelofibrosis.
作者信息
Wang Jun-Nuan, Li Yan
机构信息
Hebei Medical University Shijiazhuang, Hebei, The People's Republic of China.
Department of Hematology, Hebei General Hospital Shijiazhuang, Hebei, The People's Republic of China.
出版信息
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.
Abstract
Lymphoma is a heterogeneous malignant tumor with an increasing annual incidence. As the lymphoma progresses, bone marrow (BM) invasion gradually appears. Myelofibrosis (MF) can accompany a variety of hematological malignancies, including lymphoma, and multiple myeloma. The prognosis of lymphoma patients with myelofibrosis is poor, and a fundamental reason is that there are few studies on the correlation and pathogenesis of the two diseases. In this review, we examine the potential pathogenesis and the correlation of the two diseases.
摘要
淋巴瘤是一种异质性恶性肿瘤，年发病率呈上升趋势。随着淋巴瘤的进展，骨髓浸润逐渐出现。骨髓纤维化（MF）可伴发多种血液系统恶性肿瘤，包括淋巴瘤和多发性骨髓瘤。合并骨髓纤维化的淋巴瘤患者预后较差，根本原因是对这两种疾病的相关性及发病机制研究较少。在本综述中，我们探讨了这两种疾病的潜在发病机制及相关性。
相似文献
1
Exploring the molecular mechanisms between lymphoma and myelofibrosis.
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.
2
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283.
3
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Front Oncol. 2022 May 11;12:906698. doi: 10.3389/fonc.2022.906698. eCollection 2022.
4
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
5
[18F-FDG-PET/CT is effective in distinguishing myelofibrosis due to bone marrow infiltration of diffuse large B-cell lymphoma from triple-negative primary myelofibrosis].
Rinsho Ketsueki. 2017;58(3):228-232. doi: 10.11406/rinketsu.58.228.
6
Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis.
Int J Rheum Dis. 2018 May;21(5):1049-1059. doi: 10.1111/1756-185X.13308. Epub 2018 Apr 19.
7
[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):1080-1085. doi: 10.7534/j.issn.1009-2137.2017.04.021.
8
Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Hematology. 2015 May;20(4):203-7. doi: 10.1179/1607845414Y.0000000192. Epub 2014 Aug 17.
9
[Pathological Characteristics of Bone Marrow in Non-Hodgkin's Lymphoma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Jun;23(3):674-8. doi: 10.7534/j.issn.1009-2137.2015.03.014.
10
Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3.
引用本文的文献
1
F-FDG PET/CT findings in a mucosa-associated lymphoid tissue lymphoma patient coexisting with primary myelofibrosis.
Am J Nucl Med Mol Imaging. 2024 Dec 15;14(6):365-370. doi: 10.62347/BZUZ7442. eCollection 2024.
本文引用的文献
1
Mutations, inflammation and phenotype of myeloproliferative neoplasms.
Front Oncol. 2023 May 22;13:1196817. doi: 10.3389/fonc.2023.1196817. eCollection 2023.
2
NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells.
Front Immunol. 2023 Feb 23;14:1134661. doi: 10.3389/fimmu.2023.1134661. eCollection 2023.
3
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens.
Front Bioeng Biotechnol. 2023 Feb 23;11:1110765. doi: 10.3389/fbioe.2023.1110765. eCollection 2023.
4
Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway.
Molecules. 2023 Feb 27;28(5):2195. doi: 10.3390/molecules28052195.
5
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Blood. 2023 May 18;141(20):2508-2519. doi: 10.1182/blood.2022015418.
6
The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
Biomolecules. 2023 Jan 6;13(1):119. doi: 10.3390/biom13010119.
7
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.
Blood. 2022 Dec 29;140(26):2805-2817. doi: 10.1182/blood.2022017326.
8
Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
Nat Commun. 2022 Sep 13;13(1):5347. doi: 10.1038/s41467-022-32928-3.
9
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.
Cell Death Dis. 2022 May 20;13(5):481. doi: 10.1038/s41419-022-04932-4.
10
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer. 2022 Jul 1;128(13):2420-2432. doi: 10.1002/cncr.34205. Epub 2022 May 2.
Zotero 插件